Skip to main content
. 2013 Aug 1;8(8):e70442. doi: 10.1371/journal.pone.0070442

Figure 4. Geranylgeraniol co-treatment reversed ATO effect on miR-182 expression.

Figure 4

(A) PC3 cells were treated with 5 µM ATO for 48 h in the presence and absence of metabolites including geranylgeraniol (10 µM) and farnesol (10 µM), miR182 expression was then detected by qRT-PCR. (B) PC3 cells were treated with 5 µM ATO for 2 or 4 days in the presence and absence of geranylgeraniol (10 µM) and farnesol (10 µM), cell proliferation (4 day treatment) was evaluated by MTT assay and LC3-II expression (2 day treatment) was examined by western blot. (C) PC3 cells were cultured in normal growth medium (10% FBS) overnight, and were then stressed by culturing in low serum medium (1% FBS) for 48 h, followed by quantitation of miR-182 expression by qRT-PCR. (D) p53 expression was examined by western blot analysis in PC3 cells, MDA-MB-231 breast cancer cells served as a positive control for p53 expression. For all bar graphs, data are expressed as Mean ± SD; for qRT-PCR analyses, n = 3; for MTT assay, n = 8; *p<0.05, **p<0.01, ***p<0.001.